# Cipherome, Inc.

> Cipherome is a San Jose-based clinical genomics and bioinformatics company on a mission to find the drug that works for each individual. Its no-code platform COMPASS lets researchers transform, query, and analyze massive clinical and genomic datasets - like the 500,000-participant UK Biobank - without writing code, while its Xentinel platform uses explainable AI to predict and reduce adverse drug reactions. Backed by roughly $16-23M through a Series B, the 12-person team pairs Silicon Valley software with Seoul National University biomedical-informatics research.

- **Founded:** 2015
- **Headquarters:** San Jose, California, United States
- **Founders:** Ju Han Kim (Co-Founder; Professor of Biomedical Informatics, Seoul National University), Ilsong Lee (Chief Executive Officer)
- **Team size:** ~12 employees
- **Products:** COMPASS, Xentinel, Xentinel Lighthouse
- **Notable:** Developed Xentinel, a trademarked personalized drug safety and biomarker discovery platform (USPTO Reg. No. 6096625)., Built COMPASS, a no-code platform integrated with the 500,000-participant UK Biobank and MIMIC-IV using OMOP CDM., Selected to the American Heart Association's Innovators' Network (2022).

## Products & services

- **COMPASS** — An end-to-end, no-code healthcare data analysis platform for transforming, querying, and analyzing clinical and genomic data (biobank, EHR, EDC). Handles cohort building, data extraction, visualization, statistical analysis, GWAS, and AI model training, deployable on-premises or in the cloud.
- **Xentinel** — A proprietary personalized drug safety and biomarker discovery platform that uses explainable AI and machine learning to predict adverse drug reactions and personalize drug treatment.
- **Xentinel Lighthouse** — A commercial pilot of the Xentinel platform focused on Hispanic/Latinx patients in South Texas to guide personalized prescribing.

## Achievements

- Developed Xentinel, a trademarked personalized drug safety and biomarker discovery platform (USPTO Reg. No. 6096625).
- Built COMPASS, a no-code platform integrated with the 500,000-participant UK Biobank and MIMIC-IV using OMOP CDM.
- Selected to the American Heart Association's Innovators' Network (2022).
- Raised a Series B round with investors including GC Pharma and InterVest.
- Launched the Xentinel Lighthouse pilot focused on underrepresented Hispanic/Latinx patients in South Texas.

## Latest updates

- **2024-05** — Relaunched web presence highlighting COMPASS as the flagship no-code clinical and genomic data analysis platform.
- **2022-11** — Signed an MOU with Seoul National University Bundang Hospital for cooperation in personalized medicine.
- **2022-03** — Joined the American Heart Association Center for Health Technology & Innovation's Innovators' Network.
- **2022-02** — Closed a Series B funding round (~$16.35M) with investors including GC Pharma.

## Links

- Website: https://cipherome.com
- LinkedIn: https://www.linkedin.com/company/cipherome
- Twitter/X: https://twitter.com/cipherome

---

Profile page: https://yespress.io/cipherome-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-13